We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?
Read MoreHide Full Article
Key Takeaways
PFE's oncology revenues rose 7% in Q1 2025, aided by Xtandi, Lorbrena, Padcev and Braftovi-Mektovi.
The 2023 Seagen acquisition added four ADCs and next-gen candidates to PFE's cancer drug lineup.
PFE's 2025 EPS estimate has risen to $3.06, while its forward P/E of 7.77 remains below the industry average.
Pfizer (PFE - Free Report) is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics.
The addition of Seagen in 2023 also strengthened its position in oncology by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. The acquired Seagen products contributed meaningfully to Pfizer’s revenues in 2024 and in the first quarter of 2025. Seagen also has some next-generation ADC candidates in its pipeline.
Pfizer’s oncology revenues grew 7% on an operational basis in the first quarter of 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev.
Pfizer has also ventured into the oncology biosimilars space and markets six biosimilars for cancer. Pfizer has also advanced its oncology clinical pipeline with several candidates entering late-stage development, like sasanlimab, vepdegestrant and sigvotatug vedotin. In May, Pfizer inked an exclusive licensing deal with China's 3SBio for the latter’s dual PD-1 and VEGF inhibitor, which will strengthen its oncology pipeline.
Pfizer is also working on expanding the labels of approved oncology products like Padcev and Adcetris, among others.
With all the above developments, Pfizer’s future in cancer treatment looks promising.
For AstraZeneca, oncology sales now comprise around 41% of total revenues. Sales in its oncology segment rose 13% in the first quarter of 2025. AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-LI inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck’s pharmaceutical sales.
Bristol-Myers’ key cancer drug is PD-LI inhibitor, Opdivo, which accounts for around 20% of its total revenues.
PFE’s Price Performance, Valuation and Estimates
Pfizer’s stock has declined 6.8% so far this year against an increase of 0.2% for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company’s shares currently trade at 7.77 forward earnings, lower than 15.05 for the industry and the stock’s 5-year mean of 10.90.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has risen from $2.98 per share to $3.06 per share, while that for 2026 has gone up from $3.00 to $3.09 per share over the past 60 days.
Image: Bigstock
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?
Key Takeaways
Pfizer (PFE - Free Report) is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics.
The addition of Seagen in 2023 also strengthened its position in oncology by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. The acquired Seagen products contributed meaningfully to Pfizer’s revenues in 2024 and in the first quarter of 2025. Seagen also has some next-generation ADC candidates in its pipeline.
Pfizer’s oncology revenues grew 7% on an operational basis in the first quarter of 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev.
Pfizer has also ventured into the oncology biosimilars space and markets six biosimilars for cancer. Pfizer has also advanced its oncology clinical pipeline with several candidates entering late-stage development, like sasanlimab, vepdegestrant and sigvotatug vedotin. In May, Pfizer inked an exclusive licensing deal with China's 3SBio for the latter’s dual PD-1 and VEGF inhibitor, which will strengthen its oncology pipeline.
Pfizer is also working on expanding the labels of approved oncology products like Padcev and Adcetris, among others.
With all the above developments, Pfizer’s future in cancer treatment looks promising.
Competition in the Oncology Space
Other large players in the oncology space are AstraZeneca (AZN - Free Report) , Merck (MRK - Free Report) and Bristol-Myers (BMY - Free Report) .
For AstraZeneca, oncology sales now comprise around 41% of total revenues. Sales in its oncology segment rose 13% in the first quarter of 2025. AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-LI inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck’s pharmaceutical sales.
Bristol-Myers’ key cancer drug is PD-LI inhibitor, Opdivo, which accounts for around 20% of its total revenues.
PFE’s Price Performance, Valuation and Estimates
Pfizer’s stock has declined 6.8% so far this year against an increase of 0.2% for the industry.
From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company’s shares currently trade at 7.77 forward earnings, lower than 15.05 for the industry and the stock’s 5-year mean of 10.90.
The Zacks Consensus Estimate for 2025 earnings has risen from $2.98 per share to $3.06 per share, while that for 2026 has gone up from $3.00 to $3.09 per share over the past 60 days.
Pfizer has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.